Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16050420 | 1.00 | PTGS1 (0.31) | PTGS1PTGS2KDM4ETDP1 | |
| SCHEMBL9493755 | 0.81 | PTGS1 (0.44) | PTGS1PTGS2 | |
| SCHEMBL9493749 | 0.81 | PTGS1 (0.44) | PTGS1PTGS2 | |
| SCHEMBL16050476 | 0.76 | THRB (0.35) | PTGS1PTGS2 | |
| SCHEMBL16050474 | 0.76 | THRB (0.35) | PTGS1PTGS2 | |
| SCHEMBL25368970 | 0.75 | KDM4E (0.34) | KDM4ETDP1 | |
| SCHEMBL2554114 | 0.75 | KDM4E (0.34) | KDM4ETDP1 | |
| SCHEMBL30694796 | 0.75 | KDM4E (0.34) | KDM4ETDP1 | |
| SCHEMBL1019992 | 0.73 | KDM4E (0.43) | KDM4ETDP1 | |
| SCHEMBL8657492 | 0.73 | KDM4E (0.43) | KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2022-03-08 | — | — | US | disclosed |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-11-30 | — | — | US | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | Liminal Biosciences Limited (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200237693-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | LIMINAL BIOSCIENCES INC (GB) | 2020-07-30 | — | — | US | disclosed |
| US-20200078324-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | Liminal Biosciences Limited (GB) | 2020-03-12 | — | — | US | disclosed |
| US-10450258-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-10391073-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | PROMETIC PHARMA SMT LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-20180134649-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS,SKIN FIBROSIS AND CARDIAC FIBROSIS | PROMETIC PHARMA SMT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-9884802-B2 | Substituted aromatic compounds for the treatment pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170312237-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | Liminal Biosciences Limited (GB) | 2017-11-02 | — | — | US | disclosed |
| EP-3217968-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | PROMETIC PHARMA SMT LIMITED (GB) | 2017-09-20 | — | — | EP | disclosed |
| EP-3203999-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | PROMETIC PHARMA SMT LIMITED (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016074068-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | PROMETIC BIOSCIENCES INC. (CA) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016054728-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2016-04-14 | — | — | WO | disclosed |
| US-20160023983-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS,SKIN FIBROSIS AND CARDIAC FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2016-01-28 | — | — | US | disclosed |
| EP-2970088-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS | ProMetic BioSciences Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014138907-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | COL1A1, CCNH, COL2A1 | PTGS1 197/4885PTGS2 322/4885KDM4E 1096/4885 |
| US-20170312237-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | CCNH, COL1A1, COL2A1 | PTGS1 224/4885PTGS2 263/4885KDM4E 1142/4885 |
| US-20200237693-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ADIPOR1, ADIPOR2, FN1 | PTGS1 2271/4885PTGS2 2609/4885KDM4E 1479/4885 |
| US-10391073-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | CCNH, COL1A1, COL2A1 | PTGS1 224/4885PTGS2 263/4885KDM4E 1142/4885 |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | COL1A1, CCNH, COL2A1 | PTGS1 197/4885PTGS2 322/4885KDM4E 1096/4885 |
| US-20160023983-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS,SKIN FIBROSIS AND CARDIAC FIBROSIS | PAH, HRH3, CFH | PTGS1 1304/4885PTGS2 1591/4885KDM4E 1111/4885 |
| US-10450258-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | PTGS1 1304/4885PTGS2 1591/4885KDM4E 1111/4885 |
| US-20200078324-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | COL1A1, COL2A1, CCNH | PTGS1 194/4885PTGS2 397/4885KDM4E 1136/4885 |
| US-20180134649-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS,SKIN FIBROSIS AND CARDIAC FIBROSIS | PAH, HRH3, CFH | PTGS1 1304/4885PTGS2 1591/4885KDM4E 1111/4885 |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | ADIPOR1, ADIPOR2, FN1 | PTGS1 2271/4885PTGS2 2609/4885KDM4E 1479/4885 |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | PTGS1 1304/4885PTGS2 1591/4885KDM4E 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.